Hepion Pharmaceuticals’ (NASDAQ:HEPA) shares are on the surge today after the biopharmaceutical company posted positive topline results from a Phase 2 study evaluating rencofilstat in non-alcoholic steatohepatitis (NASH).
The trial met its primary as well as all secondary efficacy endpoints with rencofilstat displaying the highest benefit to liver function at 225mg dose. The company is currently recruiting for the larger and longer Phase 2b study of the drug.
Rencofilstat, Hepion’s lead candidate, has received orphan drug designation in NASH as well as fast-track designation in hepatocellular carcinoma (HCC) from the U.S. Food and Drug Administration.
With today’s price gains, Hepion shares have now surged nearly 121.5% year-to-date.
Read full Disclosure